An important issue in allogeneic peripheral blood progenitor cell transplantation is the optimization of the regimen of mobilization of progenitor cells from normal donors. It has been shown that for G-CSF doses up to 10 g/kg/day, a dose-response relationship exists for the degree of progenitor cell mobilization. Formal comparisons with doses higher than 10 g/kg/day, however, have not been reported. The aim of this study was to compare the mobilization and collection results of two different G-CSF (Filgrastim) schedules: 10 g/kg/12 h (n = 20; group A) vs 10 g/kg/24 h (n = 20; group B). Apheresis sessions were started on day 5 (after 4 days of G-CSF). Adverse events consisted of bone pain, headache, and fatigue which required treatment with acetaminophen ± codeine in both donor groups. Discontinuation of G-CSF administration for intolerable sideeffects was not necessary in any case. The increase in peripheral leukocyte and lymphocyte counts × 10 9 /l on day 5 was higher in group A (56.2 (37.1-75.2) and 4.4 (2.1-14.6), respectively) than in group B (27.5 (13.2-53.9) and 2.6 (1.9-5.1), respectively) (P Ͻ 0.0001 and P = 0.008). Platelets × 10 9 /l decreased in group A from 228 (161-286) before G-CSF administration to 207 (155-328) on day 5 (P = 0.03), whereas no change was observed in group B. Following the first apheresis, a significant decrease in platelet count was observed with both G-CSF schedules without any differences between groups. The number × 10 6 /kg of both nucleated and CD34 + cells collected after the first apheresis session was higher in group A (672 (462-992) and 5.9 (3.4-10.4), respectively) than in group B (427 (319-608) and 3.1 (1.1-6.8), respectively) (P = 0.0003 in both cases). The median number of CD3 + cells × 10 6 /kg collected after one apheresis session was similar with both G-CSF schedules (212 (91-430) in group A and 170 (110-291) in group B) (P = NS). In conclusion, the schedule of 10 g/kg/12 h was well tolerated and resulted in the collection of a higher number of progenitor cells than 10 g/kg/24 h without increasing the T cell content. This approach could avoid the donor having to undergo a second apheresis, and facilitate further graft manipulation.
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Mobilized peripheral blood progenitor cells (PBPC) are increasingly being used for allogeneic transplantation. [1] [2] [3] [4] The advantage of PBPC donation in comparison to bone marrow aspiration is that the risks and discomfort associated with the surgical procedure are avoided. On the other hand, the disadvantages of PBPC donation consist of the exposure to hematopoietic growth factor and the need for one or more leukapheresis sessions, which are not without side-effects. 5, 6 Although the short-term safety profile of G-CSF is well known, its optimal dose and schedule to ensure the collection of an adequate number of progenitor cells while minimizing toxicity to the donors have not been established. It has been shown that for G-CSF doses up to 10 g/kg/day, a relationship exists between the G-CSF dose and the degree of PBPC mobilization. 2, [7] [8] [9] Although experience with higher doses is limited, a recent report has suggested that they could be more effective with only a minor increase in toxicity. 10 Thus, the administration of high doses of G-CSF might enhance the quantity of stem cells collected, reducing the number of apheresis sessions and facilitating further graft manipulation such as T celldepletion (TCD) procedures. Moreover, recent reports suggest that the infusion of a large number of hematopoietic progenitor cells could improve the quality of engraftment and survival in allogeneic transplantation. [11] [12] [13] This is of special interest in the setting of mismatched and haploidentical transplants in which TCD of the graft is usually required to reduce the incidence of graft-versus-host disease.
These observations were the background for the evaluation of a schedule with high-dose G-CSF in order to improve the CD34 + cell content of TCD PBPC transplants. In the present study we have compared, in terms of mobilization efficacy and toxicity, a G-CSF dose of 10 g/kg/12 h with the conventional schedule of 10 g/kg/24 h.
Materials and methods

Donors and G-CSF administration
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donor before starting the procedure. The protocol and consent forms were approved by the Hospital Clinical Ethics Committee and by the Spanish Ministry of Health. Donors received recombinant human G-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) by subcutaneous injection for 4-5 consecutive days at a dose of 10 g/kg/12 h (n = 20, group A) or 10 g/kg/24 h (n = 20, group B). The schedule of 10 g/kg/12 h of G-CSF was applied in those cases in which a further T cell depletion of the harvest was planned, in order to increase the stem cell content of the harvest and to improve the results of the graft manipulation. The median age of the donors was 38 years (range 18-60) for group A and 36 years (range 24-61) for group B (P = NS). Donor and recipient weight and blood volume processed by apheresis were also comparable for both groups ( Table 1) . The treatment was performed on an outpatient basis in all cases.
PBPC collection
Apheresis sessions were started on day 5 of G-CSF administration, 12 h (group A) or 16-18 h (group B) after the last dose of G-CSF. Aphereses were performed with a Fenwall CS3000 Plus blood-cell separator (Baxter, Deerfield, IL, USA), processing 10-12 l of blood daily at flow rates of 50-60 ml/min using antecubital veins in all donors.
Cell characterization
Peripheral blood samples were obtained from the donors for WBC, lymphocyte, platelet and hemoglobin analysis prior to G-CSF administration, daily, and just before and after the apheresis procedure (day 5). A complete blood count was determined using an automated cell counter (Technicon H*2 and H*3, Bayer Diagnostics, Tarrytown, USA). CD3 + and CD34 + cell quantification was performed on the unfractioned apheresis product using the following monoclonal antibodies (moAb): fluorescein isothiocyanate (FTIC)-conjugated anti-CD3 (leu-4), phycoerythrin (PE)-conjugated anti-CD34 (anti-HPCA-2), FITC-anti-CD45, PE-anti-CD14, and Simultest Control (IgG1 FITC + IgG2a PE), all purchased from Becton Dickinson Immunocytometry Systems (BDIS), San Jose, CA, USA. FACS Lysing Solution (BDIS) was used to lyse erythrocytes after staining. Flow cytometry was performed on a FACScan (BDIS) equipped with a 15-mW air-cooled argon-ion laser tuned at 488 nm. Data were analyzed using the software Lysis II. For the purpose of CD34 + cell analyses, a gate for viable cells excluding erythrocytes and debris was set according to forward (FSC) and side light scatter (SCC). The CD34 + cells were analyzed in a fluorescence vs SCC plot. Thus, only cells with low SCC were counted as CD34 + cells. A minimum of 75 000 events within the acquisition gate were stored in listmode data files for further analysis. The percentage of cells labeled with the particular moAb was multiplied by the total WBC/l to give the total antibodypositive cells in the apheresis product.
Statistics
The number of nucleated, CD34
+ and CD3 + cells collected after apheresis sessions are expressed × 10 6 /kg of donor body weight. Median values and ranges for each parameter were determined. The probability of significant differences between groups was assessed by the nonparametric MannWhitney U test. The analysis was performed with SPSS software. 
G-SCF stopped in 5 cases
Days of G-CSF administration 
Results
Donor side-effects
As shown in Table 1 , adverse events consisted of mild to moderate bone pain, headache, fatigue and arthralgias which required treatment with oral acetaminophen (500-1500 mg p.o. per day) ± codeine (14-42 g p.o. per day) in both donor groups (Table 1) . One donor from group B presented with fever after 4 days of G-CSF administration. These side-effects disappeared rapidly after the last application of G-CSF. Discontinuation of G-CSF administration because of intolerable side-effects was not necessary in any case.
Peripheral blood cell counts
G-CSF administration resulted in an increase in peripheral WBC count (× 10 9 /l) on day 5 which was significantly higher in group A (median: 56.2, range: 37.1-75.2) than in group B (median: 27.5, range: 13.2-53.9) (P Ͻ 0.0001, Table 2 and Figure 1 /l, respectively, before G-CSF administration on day 5. G-CSF treatment was interrupted in all these cases, the WBC count being less than 70 × 10 9 /l on the next day.
Peripheral blood lymphocytes (× 10 9 /l) were significantly increased on day 5 compared with baseline values in both groups (group A, P = 0.001; and group B, P = 0.0003). These values were higher in donors from group A (median: 4.4, range: 2.1-14.6) than in group B (median: 2.6, range: 1.9-5.1) (P = 0.0006, Table 2 ).
Platelet count (× 10 9 /l) slightly decreased in group A from a median (range) of 228 (161-286) before G-CSF administration to 207 (155-328) on day 5 (P = 0.03), whereas no changes were observed in group B (Table 2) . Hemoglobin levels were not modified. Following the first apheresis, a significant decrease in platelet count (× 10 9 /l) was observed with both G-CSF schedules, from a median (range) of 207 (155-328) on day 5 to 137 (96-198) in group A (P = 0.0007), and from 221 (143-270) to 143 (75-218) in group B (P = 0.0003), without differences between groups (Table 2) .
Cell harvests
The number (× 10 6 /kg of donor body weight) of nucleated cells and CD34 + cells collected after the first apheresis session was higher in group A (672 (462-992) and 5.9 (3.4-10.4), respectively) than in group B (427 (319-608) and 3.1 (1.1-6.8), respectively) (P = 0.0003 in both cases). This resulted in the collection of a median (range) of CD34 (Table 3) . Two cases from group B were considered poor mobilizers since three and four apheresis sessions were needed, respectively, for a minimum yield of 2 × 10 (Figure 2) . 
Table 3
Number of apheresis sessions required in group A (10 g/kg/12 h) and in group B (10 g/kg/24 h) for a yield of у3 × 10 6 /kg of CD34 + cells
No. of apheresis sessions Group A (%) Group B (%)
1 18 (90) 8 (40) 2 2 (10) 10 (50) у3 0 (0) 2(10)
Discussion
The optimal dosing schedule of G-CSF for PBPC mobilization in normal donors for allogeneic transplantation is still under investigation, although most centers use 10 g/kg/day in a single subcutaneous dose. On the basis of available data, it appears that for doses between 5 and 10 g/kg/day, a relationship exists between the G-CSF dose and the degree of progenitor cell mobilization. 2,7-9 The advantage of higher doses, however, remains controversial. In the study of Majolino et al 14 no statistical difference was found between 10 g/kg/day and 16 g/kg/day, while Waller et al 15 reported that G-CSF 10 g/kg twice daily was superior to a single dose of 10 g/kg in normal subjects. Recently, a randomized study in patients showed that doses of 30 g/kg were more effective than 10 g/kg with only a minor increase in toxicity. 10 Our results are consistent with these latter observations, showing that the number of CD34
+ cells collected with a single apheresis session with the 10 g/kg/12 h schedule is significantly higher than with 10 g/kg/24 h. The superiority of high doses of G-CSF could be explained by its pharmacokinetic profile. Faulkner et al 16 observed that the clearance of G-CSF is strikingly increased in the range of absolute neutrophil count (ANC) generally reached during PBPC collections. Thus, when the ANC is Ͻ5 × 10 9 /l, a G-CSF dose of 5 g/kg/day is probably sufficient to provide serum levels above the maximal clonogenic precursor stimulation threshold, while for an ANC Ͼ20 × 10 9 /l, higher doses of G-CSF might be needed to provide mobilizing G-CSF serum levels. Another factor that could contribute to the improved PBPC collection of the 10 g/kg/12 h schedule might be the timing of cytokine application. Kinetic studies showed that the highest CD34 + cell count in peripheral blood is reached 6-12 h after G-CSF injection. 17 In fact, a 5 g/kg dose twice daily has been reported to be a potentially superior mobilizing regimen compared to 10 g/kg in a single dose. 18, 19 Although there is no universal agreement on the optimal CD34 + cell dose for transplantation, a dose-response relationship between the number of CD34
+ cells infused and the rate of hematopoietic recovery has been reported. 20, 21 In the setting of allogeneic transplantation, recent reports suggest that increasing the number of hemopoietic progenitors would not only accelerate the hemopoietic recovery and shorten the hospital stay, but may also lead to reduced complications and increased survival. [11] [12] [13] Therefore, collecting the maximum quantity of CD34 + cells with the minimum risk and inconvenience for the donor seems to be a desirable goal. In addition, if further graft manipulation such as positive selection of CD34 + cells is considered, this goal could be of particular relevance, since between 35 and 50% of CD34 + cells are lost during the procedure. 22 In our experience, G-CSF at 10 g/kg/12 h ensured in most of the cases that adequate quantities of CD34 + cells are yielded after one apheresis session without increasing T cell content and thus facilitating graft manipulation.
Typical side-effects of G-CSF priming are bone pain, myalgia and headaches. 5 Although a correlation between G-CSF dose and adverse events has been suggested, in the present study donors receiving the higher dose of G-CSF did not appear to have more severe side-effects than those treated with the lower dose. With respect to the hematological effects of G-CSF, dose reduction of G-CSF has been recommended by several investigators when excessive leukocytosis is reached, which has arbitrarily been defined as a leukocyte count of more than 70 × 10 9 /l. We observed a significant increase in the total WBC count in all donors, reaching values Ͼ70 × 10 9 /l (maximum: 75 × 10 9 /l) in five cases treated with 10 g/kg/12 h on the last day of G-CSF administration, without any related complication. In fact, a correlation between the degree of leukocytosis and toxicity has not been established in humans. We also found a slight and clinically irrelevant decrease in platelet count on day 5 before the apheresis procedure with the 10 g/kg/12 h schedule. This effect may be attributed to G-CSF administration and could be dose-related since donors treated with 10 g/kg/day did not present it. 23, 24 Platelet depletion secondary to the leukapheresis procedure had, however, a similar intensity in both groups of donors. Besides thrombocytopenia, a transient reduction in neutrophil and lymphocyte counts below baseline levels has been described after PBPC donation. 4, 6, 25 Although a direct role of G-CSF cannot be ruled out, the leukapheresis procedure itself seems to be mainly responsible. Thus, the number of apheresis procedures is critical for the donor, and may vary with the dose and schedule of G-CSF. Our results show that 10 g/kg/12 h of G-CSF leads to the collection of a high number of progenitor cells by means of only one apheresis session without increasing toxicity. Therefore, the use of high-dose G-CSF schedules could reduce the intensity of cytopenias post donation and the personnel time required for harvesting.
In conclusion, the data presented here support that 10 g/kg/12 h of G-CSF is a well tolerated regimen that results in high yields of CD34 + cells in the leukapheresis product. Whereas 10 g/kg/24 h could be the effective dose of G-CSF for adequate PBPC mobilization in the majority of normal donors, if a manipulation of the graft is planned, a G-CSF dose of 10 g/kg/12 h might be considered.
